EMJ Hematology 11 [Supplement 3] . 2023

This article highlights key insights from a symposium on treatment options for patients with relapsed/refractory diffuse large B cell lymphomas (DLBCL) who are not eligible for autologous stem cell transplant, and where chimeric antigen receptor T cell therapy is not appropriate. It was delivered at the International Conference on Malignant Lymphoma (ICML) Congress, which took place in Lugano, Switzerland, on 13^th June 2023. The expert panellists explored treatment decisions for different patients and emphasised the need for multidisciplinary team input and patient and caregiver inclusion.